Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

3 Unprofitable Stocks in Hot Water

By: StockStory

June 11, 2025 at 00:34 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

DNUT Cover Image

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. Keeping that in mind, here are three unprofitable companiesto steer clear of and a few better alternatives.

Krispy Kreme (DNUT)

Trailing 12-Month GAAP Operating Margin: -2.6%

Famous for its Original Glazed doughnuts and parent company of Insomnia Cookies, Krispy Kreme (NASDAQ: DNUT) is one of the most beloved and well-known fast-food chains in the world.

Why Do We Pass on DNUT?

Earnings per share have contracted over the last three years, a headwind for returns as stock prices often echo long-term EPS performance
Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
Short cash runway increases the probability of a capital raise that dilutes existing shareholders

Krispy Kreme’s stock price of $2.98 implies a valuation ratio of 29.2x forward P/E. Dive into our free research report to see why there are better opportunities than DNUT.

NeoGenomics (NEO)

Trailing 12-Month GAAP Operating Margin: -13.3%

Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ: NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers.

Why Do We Think NEO Will Underperform?

Earnings per share fell by 12% annually over the last five years while its revenue grew, partly because it diluted shareholders
Push for growth has led to negative returns on capital, signaling value destruction, and its falling returns suggest its earlier profit pools are drying up
Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders

NeoGenomics is trading at $7.89 per share, or 35.1x forward P/E. Read our free research report to see why you should think twice about including NEO in your portfolio.

LifeStance Health Group (LFST)

Trailing 12-Month GAAP Operating Margin: -1%

With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ: LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.

Why Does LFST Give Us Pause?

Subscale operations are evident in its revenue base of $1.28 billion, meaning it has fewer distribution channels than its larger rivals
Cash-burning history makes us doubt the long-term viability of its business model
Negative returns on capital show management lost money while trying to expand the business

At $5.89 per share, LifeStance Health Group trades at 75.3x forward P/E. If you’re considering LFST for your portfolio, see our FREE research report to learn more.

Stocks We Like More

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	266.32	-2.14 (-0.80%)
AAPL	308.82	+3.83 (1.26%)
AMD	467.51	+17.92 (3.99%)
BAC	51.80	+0.31 (0.60%)
GOOG	379.38	-4.09 (-1.07%)
META	610.26	+2.88 (0.47%)
MSFT	418.57	-0.52 (-0.12%)
NVDA	215.33	-4.18 (-1.90%)
ORCL	192.08	+2.31 (1.22%)
TSLA	426.01	+8.16 (1.95%)